Phase 2 Stomach Cancer Trial, Recruiting NCT06532799 Sponsor: Essen Biotech Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT06532799
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 16 and 90 years old
  • You have been diagnosed with cancer (primary, returned, or spread to other parts of the body) confirmed by a tissue test
  • Your doctors expect you to live for more than 3 months
  • You are well enough to carry out some daily activities (a doctor will assess your general health level)
  • Your cancer has not responded to standard treatments, or no standard treatments are available for your type of cancer
  • You have a tumor area that can be safely biopsied or surgically removed, or you have a body fluid (such as fluid around the lungs) that contains cancer-fighting immune cells
  • You have at least one tumor that can be measured or assessed
  • Your blood test results (taken within 7 days before joining) meet certain minimum levels for white blood cells, infection-fighting cells, clotting, kidney function, and liver function (the trial team will check these)
  • There are no medical reasons preventing you from having a biopsy or minor surgery
  • If you are able to have children, you must be willing to use reliable contraception from the time you agree to join until one year after completing a specific treatment step in the trial
  • Any cancer treatments you have received (such as radiotherapy, chemotherapy, or biological therapies) must have stopped at least 28 days before your immune cells are collected
  • You are able to understand and sign the consent form
  • You are able to attend follow-up visits and follow the trial's requirements

Who may not be able to join:

  • You need regular steroid medication (such as prednisone) at a dose higher than 15mg per day, or you have an autoimmune disease requiring immune-suppressing treatment
  • Your lung function is significantly reduced (the trial team will carry out specific breathing tests to check this)
  • You have serious heart problems, such as severe heart failure, uncontrolled low blood pressure, poor heart pumping ability, or significant heart rhythm problems
  • You have HIV, active hepatitis B or C, syphilis, or other related infections
  • You have a serious physical or mental health condition
  • You currently have an active infection that requires treatment, or there is evidence of infection in your blood or on scans
  • You have received or are currently receiving other treatments, including other medicines, biological therapies, chemotherapy, or radiotherapy within the past month
  • You have a known allergy to substances similar to those used in cell-based treatments
  • You have previously had a serious (Grade 3 or higher) immune-related side effect from immunotherapy
  • You still have significant side effects from a previous cancer treatment that have not resolved (minor issues like hair loss may not apply — confirm with trial site)
  • You are pregnant or breastfeeding
  • You have previously had an organ transplant, a stem cell transplant using donor cells, or ongoing kidney replacement therapy (such as dialysis)
  • The research team considers you unsuitable for the trial for any other medical or safety reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +12077706670

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Essen Biotech
Registry
ClinicalTrials.gov
Start date
10 September 2024
Est. completion
15 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov